Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3419 | Transpulmonary thermodilution Wiki | 1.00 |
drug128 | AZVUDINE Wiki | 1.00 |
drug1120 | Echocardiography Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D018754 | Ventricular Dysfunction NIH | 0.50 |
D018487 | Ventricular Dysfunction, Left NIH | 0.50 |
D012769 | Shock, NIH | 0.38 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Estimated number of participants: 342 participants with COVID-19 Design: Phase III, single-center, randomized, double-blind, parallel, placebo-controlled clinical study.
Description: Negative conversion rate of coronavirus viral load on day 7 of treatment compared to baseline
Measure: Negative conversion rate Time: 7th dayDescription: Negative conversion rate of coronavirus viral load on day 14 of treatment compared to baseline
Measure: Negative conversion rate Time: 14th dayDescription: Time of negative conversion of the viral load of the coronavirus
Measure: Time of negative conversion Time: 14th dayDescription: Negative conversion rate of the coronavirus viral load on days 7, 14 and 28
Measure: Negative conversion rate Time: on days 7, 14 and 28Description: Time of recovery of body temperature
Measure: Recovery of body temperature Time: 28th dayDescription: Time for improvement of respiratory signs and symptoms
Measure: Improvement of respiratory signs and symptoms Time: 28th dayDescription: Time for improvement of diarrhea, myalgia fatigue and other symptoms
Measure: Improvement of diarrhea, myalgia fatigue and other symptoms Time: 28th dayDescription: Change in blood oxygen detection rates
Measure: Change in blood oxygen detection rates Time: 28th dayDescription: Frequency of supplemental oxygenation or non-invasive ventilation
Measure: Frequency of supplemental oxygenation or non-invasive ventilation Time: 14th dayDescription: Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Measure: Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Time: 14th dayDescription: Frequency of adverse events
Measure: Frequency of adverse events Time: 14th dayDescription: Frequency of serious adverse events
Measure: Frequency of serious adverse events Time: 14th dayDescription: Proportion of moderate cases that progressed to severe cases
Measure: Proportion of moderate cases that progressed to severe cases Time: 14th dayDescription: Proportion of severe cases that worsened during treatment
Measure: Proportion of severe cases that worsened during treatment Time: 14th dayDescription: Mortality rate
Measure: Mortality rate Time: 28th dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports